Marshall Wace North America’s Acceleron Pharma XLRN Stock Holding History

Marshall Wace North America’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$398K	Buy	+2,314	New	+$303K	﹤0.01%	1170
2021 Q2	–	Sell	-90,295	Closed	-$12.2M	–	1947
2021 Q1	$12.2M	Buy	+90,295	New	+$11.7M	0.05%	354
2020 Q3	–	Sell	-108,294	Closed	-$10.3M	–	1578
2020 Q2	$10.3M	Buy	108,294 +103,349	+2,090%	+$9.96M	0.07%	264
2020 Q1	$444K	Buy	+4,945	New	+$384K	﹤0.01%	779
2019 Q4	–	Sell	-256,338	Closed	-$10.1M	–	1718
2019 Q3	$10.1M	Buy	256,338 +119,406	+87%	+$5.18M	0.06%	259
2019 Q2	$5.63M	Sell	136,932 -246,234	-64%	-$10.2M	0.03%	336
2019 Q1	$17.8M	Buy	383,166 +377,548	+6,720%	+$16.6M	0.13%	155
2018 Q4	$245K	Buy	+5,618	New	+$281K	﹤0.01%	921
2018 Q3	–	Sell	-117,693	Closed	-$5.71M	–	1529
2018 Q2	$5.71M	Buy	+117,693	New	+$4.29M	0.03%	480
2017 Q4	–	Sell	-159,799	Closed	-$5.91M	–	1699
2017 Q3	$5.91M	Buy	159,799 +136,966	+600%	+$4.75M	0.04%	503
2017 Q2	$685K	Sell	22,833 -44,730	-66%	-$1.3M	0.01%	1031
2017 Q1	$1.76M	Buy	+67,563	New	+$1.78M	0.01%	603

Other funds holding XLRN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Marshall Wace North America's XLRN Position: Q3 2021 in Review

Marshall Wace North America opened a new position in Acceleron Pharma (XLRN) in Q3 2021: 2,314 shares worth $398K. The stake represents ﹤0.01% of the portfolio and ranks #1170 among its holdings. This is a return to the name: Marshall Wace North America previously reported a position in XLRN as recently as Q1 2021.

Marshall Wace North America first reported a position in XLRN in Q1 2017 and has held it in 12 quarters since. The position peaked at $17.8M in Q1 2019. 330 funds tracked by Wall St. Rank hold XLRN as of Q3 2021.

Marshall Wace North America held 2,314 shares of Acceleron Pharma worth $398K as of Q3 2021.
Acceleron Pharma was a new Marshall Wace North America position in Q3 2021.
Acceleron Pharma made up ﹤0.01% of Marshall Wace North America's portfolio in Q3 2021, its #1170 holding.
Marshall Wace North America first reported a position in Acceleron Pharma in Q1 2017 and has held it in 12 quarters since.
Marshall Wace North America's Acceleron Pharma position peaked at $17.8M in Q1 2019.
330 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.